OpenAI Acquires Orchestra Bio to Build Out Life Sciences AI
OpenAI is buying a working drug-discovery operation rather than building one, and folding the team into Rosalind gives its life sciences models a process to run on rather than a benchmark to pass.
Reporting from 1 source: GIGAZINE.
OpenAI has acquired Orchestra Bio, a company founded in 2022 that supplies AI agents for managing the drug discovery process. The price is undisclosed; Orchestra Bio had raised about $20 million from venture firms including Andreessen Horowitz as of 2025. OpenAI will fold the team and technology into Rosalind, its AI models and tools for life sciences research, and called the integration a first step toward AI assisting scientists from discovery through development.
The acquisition gives Rosalind something beyond a model: a team that already runs AI agents across discovery work. Orchestra Bio was founded in 2022 and raised roughly $20 million from backers including Andreessen Horowitz as of 2025; OpenAI did not disclose what it paid.
OpenAI framed the combination as a starting point, describing a goal of AI helping scientists explore ideas, design experiments, analyze results, and coordinate the operations that move a promising treatment forward. The company says it wants to work with researchers and partner companies on that path.
Synthesized by Yomimono from the 1 cited source below, including Japanese-language reporting where cited, then editorially reviewed before publishing.